52 citations,
February 2003 in “Archives of dermatology” 9-cis-retinoic acid showed some effectiveness in treating AIDS-related Kaposi sarcoma but had significant side effects at higher doses.
1 citations,
June 2023 in “Advances in therapy” Ripretinib is effective and safe for treating advanced GIST in Chinese patients, particularly for non-gastric GISTs.
2 citations,
December 2023 in “Health Technology Assessment” Laser treatment and deroofing are effective options for hidradenitis suppurativa.
1 citations,
January 2023 in “Przegląd Dermatologiczny” The Polish Society of Dermatology recommends treatments for alopecia areata that vary by severity, including topical and systemic medications, with long-term maintenance important for management.
28 citations,
January 2021 in “Parkinsonism & related disorders (Online)/Parkinsonism & related disorders” Parkinson's disease is linked to skin disorders and skin cells help in studying the disease.
August 2019 in “Journal of The American Academy of Dermatology” RV3466F lotion significantly reduces hair loss and improves acute telogen effluvium.
1 citations,
July 2023 in “Cancers” Skin side effects from CDK4/6 inhibitors in breast cancer patients are generally mild and treatable, allowing most patients to continue treatment.
1 citations,
December 2012 in “Journal of dermatological science” Combining ficlatuzumab and gefitinib can cause severe scarring hair loss.
28 citations,
March 2017 in “Scientific Reports” Minoxidil may protect nerves and improve hair quality during paclitaxel treatment.
November 2024 in “Journal of Cosmetic Dermatology” Baricitinib is effective for severe alopecia areata but has some side effects.
December 2023 in “Journal of the Endocrine Society” Blocking glucocorticoid receptors improves glucose metabolism in a PCOS mouse model.
August 2023 in “International journal of research in dermatology” Janus kinase inhibitors are effective and generally safe for treating hair loss in adults with alopecia areata.
25 citations,
November 2013 in “Journal of the American Academy of Dermatology” Many patients on new leukemia drugs had mild to moderate skin reactions.
10 citations,
July 2016 in “Clinical and translational science” Sorafenib often causes mucositis, hand-foot syndrome, rash, alopecia, diarrhea, and fatigue.
40 citations,
August 2022 in “Frontiers in immunology” Blocking JAK/STAT pathways can help treat hair loss from alopecia areata.
30 citations,
May 2016 in “Expert Opinion on Biological Therapy” New treatments targeting immune pathways show promise for severe hair loss but need more research for safety and effectiveness.
4 citations,
November 2023 in “Frontiers in immunology” New treatments targeting T-cell pathways are needed for better alopecia areata management.
February 2022 in “Research Square (Research Square)” High TSPEAR levels in colorectal cancer predict worse outcomes.
January 2022 in “Research Square (Research Square)” High TSPEAR levels in colorectal cancer predict worse outcomes.
40 citations,
December 2019 in “Neurobiology of Stress” Neuroactive steroids show promise for treating mental and neurological disorders by targeting GABA_A receptors.
January 2023 in “Journal of orthopedics & bone disorders” Platelet-rich plasma may not be very effective for bone healing and hair growth due to a substance it contains that blocks these processes.
14 citations,
November 2020 in “International Journal of Molecular Sciences” Advanced therapies like gene, cell, and tissue engineering show promise for hair regrowth in alopecia, but their safety and effectiveness need more verification.
8 citations,
June 2011 in “Nature Biotechnology” Stem cell treatments can potentially treat baldness, with one trial showing hair growth after injecting a hair-stimulating complex, and no safety issues were reported.
3 citations,
May 2023 in “Clinical drug investigation” JAK inhibitors for alopecia areata are linked to minor side effects like headache and acne, but not to an increased risk of serious adverse events.
November 2019 in “Neuro-oncology” Rind-based techniques can lower scalp radiation dose and reduce hair loss in brain cancer treatment.
72 citations,
November 2015 in “Multiple Sclerosis and Related Disorders” Teriflunomide is safe and tolerable for treating relapsing-remitting multiple sclerosis, with manageable side effects.
33 citations,
January 2021 in “Aesthetic Surgery Journal” Low-Level Light Therapy (LLLT) is a safe and effective method for skin rejuvenation, acne treatment, wound healing, body contouring, and hair growth, but more well-designed trials are needed for confirmation.
22 citations,
January 2018 in “European urology focus” New drugs and combination therapies are improving treatment for lower urinary tract symptoms.
20 citations,
December 2016 in “Neurodegenerative disease management” Teriflunomide effectively reduces relapses and disability in MS and has a manageable safety profile.
12 citations,
June 2023 in “JAMA network open” JAK inhibitors effectively improve hair regrowth in alopecia areata with an acceptable safety profile.